• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    4/30/24 4:31:25 PM ET
    $AKTX
    $BCLI
    $CCM
    $CVRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AKTX alert in real time by email

    Gainers

    • Predictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 18.25% to $0.45. The company's market cap stands at $30.5 million.
    • Telomir Pharmaceuticals (NASDAQ:TELO) stock increased by 12.92% to $7.34. The market value of their outstanding shares is at $217.3 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 11.24% to $2.87. The market value of their outstanding shares is at $30.1 million.
    • TransMedics Gr (NASDAQ:TMDX) shares moved upwards by 11.02% to $104.51. The company's market cap stands at $3.4 billion. As per the press release, Q1 earnings came out today.
    • Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 10.0% to $1.54. The market value of their outstanding shares is at $12.2 million.

    Losers

    • Concord Medical Services (NYSE:CCM) stock declined by 23.3% to $0.65 during Tuesday's after-market session. The company's market cap stands at $28.3 million.
    • CVRx (NASDAQ:CVRX) shares declined by 16.19% to $13.0. The market value of their outstanding shares is at $280.7 million. As per the press release, Q1 earnings came out today.
    • Mereo BioPharma Group (NASDAQ:MREO) stock declined by 8.53% to $2.79. The company's market cap stands at $391.3 million.
    • BiomX (AMEX:PHGE) stock declined by 8.15% to $0.44. The market value of their outstanding shares is at $24.2 million.
    • 10x Genomics (NASDAQ:TXG) stock fell 8.13% to $26.9. The market value of their outstanding shares is at $3.2 billion. The company's, Q1 earnings came out today.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares fell 7.08% to $1.97. The market value of their outstanding shares is at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX
    $BCLI
    $CCM
    $CVRX

    CompanyDatePrice TargetRatingAnalyst
    10x Genomics Inc.
    $TXG
    3/31/2026Mkt Perform → Outperform
    William Blair
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    10x Genomics Inc.
    $TXG
    12/11/2025Buy → Neutral
    Citigroup
    10x Genomics Inc.
    $TXG
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    TransMedics Group Inc.
    $TMDX
    10/23/2025$148.00Hold → Buy
    Needham
    TransMedics Group Inc.
    $TMDX
    10/13/2025$145.00Buy
    Jefferies
    More analyst ratings

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Saxonov Serge

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    3/25/26 5:15:13 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Yang Jianyu

    3 - Concord Medical Services Holdings Ltd (0001472072) (Issuer)

    3/18/26 10:51:54 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

    NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL's LADAR technology combines laser-based sensing with proprietary AI algorithms to detect and respond to both UAV and ground-based intruders. BiomX intends to exercise the option subject to the closing of the underlying agreement and obtaining shareholder approval as necessary or consideration consisting of a combination of cash, promissory note, shares of common stock and warrants. Separat

    3/31/26 10:48:41 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    4/1/26 9:47:44 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.

    10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 5:26:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 4:16:24 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics upgraded by William Blair

    William Blair upgraded 10x Genomics from Mkt Perform to Outperform

    3/31/26 8:05:20 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    President & CEO Hassanein Waleed H bought $1,000,350 worth of shares (8,775 units at $114.00) (SEC Form 4)

    4 - TransMedics Group, Inc. (0001756262) (Issuer)

    11/18/25 4:30:07 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

    Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one new drug – Preservative Free Ketamine under an ANDA—during Q3 2026. A favorable preliminary bioequivalence determination was received from the FDA last week.A Type C in-person meeting wi

    3/24/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

    ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025. Recent Highlights Total revenue of $160.8 million in the fourth quarter of 2025, a 32% increase compared to the fourth quarter of 2024Total revenue of $605.5 million in the full year 2025, a 37% increase compared to the full year 2024Generated net income of $105.4 m

    2/24/26 4:05:00 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKTX
    $BCLI
    $CCM
    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 4:18:45 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care